Long-term efalizumab helps maintain gains of psoriasis therapy. : An article from: Skin & Allergy News
Product Description
This digital document is an article from Skin & Allergy News, published by International Medical News Group on March 1, 2002. The length of the article is 411 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after buy. You can view it with any web browser.
Citation Details
Title: Long-term efalizumab helps maintain gains of psoriasis therapy. (Excellent Compliance).(Xanelim tested by Genentech Inc.)
Author: Norra MacReady
Publication: Skin & Allergy News (Magazine/Journal)
Date: March 1, 2002
Publisher: International Medical News Group
Volume: 33 Issue: 3 Page: 6(1)
Article Type: Product/Service Evaluation
Distributed by Thomson Gale
